Image Source: Unsplash

Introduction

The Canadian Cannabis LP Stocks Portfolio continued to reel last week from the August 26th announcement by the Drug Enforcement Administration that it had scheduled an administrative hearing for December 2nd to consider differing expert opinions on the Justice Department’s proposal that cannabis be re-classified to that of a Schedule III drug under the Controlled Substances Act. That is seen as just another delay in the re-classification becoming a reality, and, as a result, ALL of the constituents in our Canadian Cannabis LP Portfolio declined dramatically over the week ending September 6th.

Our Canadian Cannabis LP Portfolio
 

Here’s what happened last week, in descending order, for the 5 largest Canadian Licensed Producers and for the previous week:

1. Tilray Brands (TLRY):
   • DOWN 5.3% w/e Sept. 6th
   • DOWN 11.4% w/e August 30th
2. Organigram (OGI):
   • DOWN 5.4% w/e Sept. 6th
   • DOWN 8.4% w/e August 30th
3. Cronos Group (CRON):
   • DOWN 5.7% w/e Sept. 6th
   • DOWN 3.0% w/e August 30th
4. Aurora Cannabis (ACB):
   • DOWN 11.0% w/e Sept. 6th
   • DOWN 6.6% w/e August 30th
5. Canopy Growth (CGC):
   • DOWN 14.0% w/e Sept. 6th
   • DOWN 16.1% w/e August 30th

Summary
 

The Canadian Cannabis LP Stocks Portfolio went DOWN 10.0% w/e Sept. 6th on top of a 9.1% decline w/e August 30th, and is now DOWN 2.1% YTD.

More By This Author:

Our 6-Part Computer Chips Portfolio Was Down 2% In August
These AI-Related Stocks Were Down +10% Week Ending September 6
Our Micro/Small Cap AI Stocks Portfolio Went Down 5% In August